Original articleLive-birth rates in very poor prognosis patients, who are defined as poor responders under the Bologna criteria, with nonelective single embryo, two-embryo, and three or more embryos transferred
Key Words
Cited by (0)
N.G. and D.H.B. are coinventors on a number of U.S. patents claiming therapeutic benefits from androgen supplementation in women with low functional ovarian reserve. Both receive royalties from Fertility Nutraceuticals, LLC, in which N.G. also holds shares. They report no other potential conflicts. M.V.V. has nothing to disclose. S.K.D. has nothing to disclose. A.W. has nothing to disclose. Y.-G.W. has nothing to disclose. Q.W. has nothing to disclose. L.Z. has nothing to disclose. D.F.A. has nothing to disclose. V.A.K. has nothing to disclose.
M.V.V. completed this work in fulfillment of a senior residency elective in reproductive endocrinology and infertility at the Center for Human Reproduction.
This study was funded by intramural funds from the Center for Human Reproduction and by grants from the Foundation for Reproductive Medicine.